camptothecin has been researched along with Kaposi Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Liu, G | 1 |
| Boyer, JC; Estabrooks, LL; Kaufmann, WK; Wilson, SJ | 1 |
| Makinson, TA; Smith, PJ; Watson, JV | 1 |
3 other study(ies) available for camptothecin and Kaposi Disease
| Article | Year |
|---|---|
DNA polymerase eta, the product of the xeroderma pigmentosum variant gene and a target of p53, modulates the DNA damage checkpoint and p53 activation.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Base Sequence; Camptothecin; Cell Cycle Proteins; Cell Line; DNA Damage; DNA Repair; DNA-Binding Proteins; DNA-Directed DNA Polymerase; DNA, Complementary; Genetic Variation; Humans; Models, Biological; Protein Serine-Threonine Kinases; RNA, Small Interfering; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Ultraviolet Rays; Xeroderma Pigmentosum | 2006 |
Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes.
Topics: Amsacrine; Ataxia Telangiectasia; Camptothecin; Cell Line; DNA; DNA Damage; DNA Replication; Drug Resistance; Humans; Kinetics; Replicon; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xeroderma Pigmentosum | 1991 |
Enhanced sensitivity to camptothecin in ataxia-telangiectasia cells and its relationship with the expression of DNA topoisomerase I.
Topics: Ataxia Telangiectasia; Camptothecin; Cell Cycle; Cell Line; Cell Line, Transformed; Cell Survival; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Fibroblasts; Humans; In Vitro Techniques; Xeroderma Pigmentosum | 1989 |